Companies · Biotechnology
BALTIMORE · Biotechnology
Diligence memoA one-page analyst read on Mi-Helper, Inc. — recommendation, valuation, rhythm, risks.→Mi-Helper, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Mi-Helper, Inc. is one of 4291 Biotechnology companies tracked from BALTIMORE. By capital raised it ranks mid-pack (ahead of 40% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 40% of sector peers (real $). Modeled value above 45% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #8 of 207.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Mesentech Inc. | Seed | $3.9M | $65.6M | 4.61× |
| Marlinspike Therapeutics, Inc. | Seed | $3.5M | $64.3M | 4.52× |
| Microbial Machines, Inc. | Seed | $3.9M | $63.6M | 4.47× |
| Pearl Diagnostics, Inc. | Seed | $3.5M | $62.8M | 4.41× |
| Crossfire Medical Inc | Seed | $3.0M | $57.5M | 4.04× |
| Design Pharmaceuticals, Inc. | Seed | $3.0M | $56.9M | 4.00× |
| Tekv Holdings LLC | Seed | $4.0M | $55.4M | 3.89× |
| Mi-Helper, Inc. this company | Seed | $4.0M | $50.9M | 3.58× |
| Thelium Therapeutics Inc. | Seed | $3.1M | $50.7M | 3.56× |
| Turtle Health, Inc. | Seed | $2.7M | $49.1M | 3.45× |
| Accufix Holdings, Inc. | Seed | $4.2M | $46.7M | 3.28× |
| Kyttaro Ltd | Seed | $5.2M | $45.5M | 3.20× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $4.0M | 2022-10-03 | $20.0M | $50.9M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Brian E. Lipford | — | — | 2022-10 |
| Eileen E. O'Rourke | — | — | 2022-10 |
| Harikrishna E. Tandri | — | — | 2022-10 |
| Keith E. Sullivan | — | — | 2022-10 |
| Steven E. Schaefer | — | — | 2022-10 |
Mi-Helper, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Tekv Holdings LLC | Biotechnology | Seed | $4.0M | $55.4M | same sector · same stage |
| Accufix Holdings, Inc. | Biotechnology | Seed | $4.2M | $46.7M | same sector · same stage |
| CannTrust Inc. | Biotechnology | Seed | $3.8M | $44.4M | same sector · same stage |
| KeriCure Inc | Biotechnology | Seed | $3.8M | $44.2M | same sector · same stage |
| VuEssence, Inc. | Biotechnology | Seed | $3.8M | $46.6M | same sector · same stage |
| Tangible Science, Inc. (fka Tangible Science, LLC) | Biotechnology | Seed | $4.3M | $59.9M | same sector · same stage |
| Intuitive Biosciences, Inc. | Biotechnology | Seed | $3.6M | $54.3M | same sector · same stage |
| Figure 8 Surgical Inc. | Biotechnology | Seed | $3.6M | $55.3M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Mimerigen, Inc. | Biotechnology | Pre-Seed | $471K | 88% |
| Arbor Biotechnologies, Inc. | Biotechnology | Series D+ | $5.7B | 86% |
| Access Bio, Inc. | Biotechnology | Series A | $300.7M | 85% |
| Metagenomi Technologies, LLC | Biotechnology | Series D+ | $1.7B | 85% |
| Genome Insight, Inc. | Biotechnology | Series A | $39.9M | 84% |
| SMSbiotech, Inc. | Biotechnology | Series B | $64.5M | 84% |
| Judo Bio Inc. | Biotechnology | Series B | $172.0M | 84% |
| Serimmune Inc. | Biotechnology | Series A | $83.3M | 84% |
See where Mi-Helper, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Mi-Helper, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.